Significantly lower risk is seen for hospitalization. One study shows significant benefit.
Meta analysis using the most serious outcome reported shows 46% [-173‑89%] lower risk, without reaching statistical significance. Early treatment is more effective than late treatment. Currently all studies are RCTs.
Currently there is limited data, with only 885 patients and only 37 control events for the most serious outcome in trials to date. Studies to date are from only 2 different groups.
Ensovibep requires IV infusion, but may be less variant dependent than monoclonal antibodies.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. All data and sources to reproduce this analysis are in the appendix.
Covid Analysis et al., Dec 2024, preprint, 1 author.
